{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:17:18Z","timestamp":1792048638083,"version":"4.4.0"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Systemic juvenile idiopathic arthritis (sJIA) is a distinct disease subset, with a poorer prognosis compared with other JIA subsets. Tocilizumab has an important role in the management of sJIA refractory to standard initial therapy. However, no specific guidelines exist for the tapering of tocilizumab therapy in sJIA, which could have implications on the overall cost and side effects of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was an observational study which included 21 children with refractory sJIA, who were initially put on injection tocilizumab every 2 weekly, with subsequent dosing tapered to 4 weekly and 6 weekly intervals based on JIA ACR 70 responses at 12 and 24\u2009weeks, respectively. The primary outcome at week 36 included JIA ACR 30, 50, 70, and 90 response rates with other efficacy and safety measures as secondary outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At 36\u2009weeks, JIA ACR 30, 50, 70, and 90 responses were observed in 90.5%, 90.5%, 71.4%, and 52.4% patients respectively along with significant improvement in hematological and inflammatory parameters. The mean prednisolone dose could be reduced from 0.54 to 0.13\u2009mg\/kg\/day and around 29% patients were able to discontinue steroids altogether. No serious adverse events were recorded. With drug tapering, we could curtail on 26% of the total tocilizumab dose that would have been otherwise required on the continuous 2 weekly protocol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Tocilizumab, used in an early response\u2010based tapering regimen, was both safe and efficacious in children with sJIA refractory to standard therapy. Larger and longer duration studies are required to further validate our observations.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.15196","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T06:59:15Z","timestamp":1716274755000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of an early response\u2010based tapering regimen of tocilizumab in children with systemic juvenile idiopathic arthritis"],"prefix":"10.1111","volume":"27","author":[{"given":"Soumya","family":"Dey","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology Institute of Postgraduate Medical Education and Research  Kolkata West Bengal India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9306-545X","authenticated-orcid":false,"given":"Debaditya","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology Institute of Postgraduate Medical Education and Research  Kolkata West Bengal India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradyot","family":"Sinhamahapatra","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology Institute of Postgraduate Medical Education and Research  Kolkata West Bengal India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2956-9703","authenticated-orcid":false,"given":"Alakendu","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology Institute of Postgraduate Medical Education and Research  Kolkata West Bengal India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60244-4"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60363-8"},{"key":"e_1_2_14_4_1","first-page":"390","article-title":"International league of association for rheumatology (ILAR) classification of juvenile idiopathic arthritis: second revision, Edmonton 2001","volume":"31","author":"Petty RE","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.68"},{"issue":"2","key":"e_1_2_14_6_1","first-page":"203","article-title":"Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease?","volume":"25","author":"De Benedetti F","year":"1998","journal-title":"J Rheumatol"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050473"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60454-7"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.134254"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112802"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205099"},{"key":"e_1_2_14_12_1","volume-title":"ACTEMRA (tocilizumab) injection, for intravenous use injection, for subcutaneous use [package insert]","author":"ACTEMRA","year":"2014"},{"key":"e_1_2_14_13_1","unstructured":"National Cancer Institute Common Toxicity Criteria 1999.http:\/\/ctep.cancer.gov\/reporting\/CTC\u20103.html"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400703"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130690"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-eular.2785"},{"issue":"1","key":"e_1_2_14_17_1","first-page":"i56","article-title":"O43 5\u2010year data from tender, a phase III clinical trial: safety and efficacy of tocilizumab in patients with systemic juvenile idiopathic arthritis","volume":"55","author":"Baildam E","year":"2016","journal-title":"Rheumatology"},{"issue":"4","key":"e_1_2_14_18_1","first-page":"421","article-title":"Efficacy and safety of humanized interleukin\u20106 receptor antibody in treatment of systemic juvenile idiopathic arthritis","volume":"46","author":"Zou L","year":"2017","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"issue":"3","key":"e_1_2_14_19_1","first-page":"260","article-title":"Biologicals in juvenile idiopathic arthritis","volume":"53","author":"Saini I","year":"2016","journal-title":"Indian Pediatr"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-13-4"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-12-S1-O13"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.15196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T08:12:08Z","timestamp":1716797528000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.15196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/1756-185X.15196"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.15196","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"2023-10-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e15196"}}